JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus

Figure 7

CD8 E percentages in JCV-DNA+ and JCV-DNA− samples, after stratification according to anti-JCV specific serology and natalizumab infusion number. (a) Comparison of CD8 E percentages between JCV-DNA+ (plasma and/or urine) and JCV-DNA− samples in patients with either positive or negative JCV serology (JCV-Ab+ and JCV-Ab−, resp.). For JCV-Ab+, 13.4%   versus 7.8%  ; for JCV-Ab−, 13.2%   versus 8.2%  , respectively. Data are shown as median [interquartile range]. Statistical analysis was performed using the 2-tailed Mann–Whitney test ( and for JCV-Ab+ and JCV-Ab− groups, resp.). (b) Comparison of CD8 E percentages between JCV-DNA+ (plasma and/or urine) and JCV-DNA− samples in patients with positive JCV serology (JCV-Ab+), after stratification according to natalizumab infusion number: for 0: 6.4%   versus 7.0%  , 12: 14.1%   versus 7.8%  , 24: 13.4%   versus 7.3%  , 36: 11.3%   versus 10.2%  , and : 12.5%   versus 6.5%  . Data are shown as median [interquartile range]. Statistical analysis was performed using the 2-tailed Mann–Whitney test (, , , , and , for 0, 12, 24, 36, and , resp.). (c) Comparison of CD8 E percentages between JCV-DNA+ (plasma and/or urine) and JCV-DNA− samples in patients with negative JCV serology (JCV-Ab−), after stratification according to natalizumab infusion number: for 0: 6.6%   versus 5.1%  , 12: 15.4%   versus 12.0%  , 24: 13.8%   versus 8.4%  , 36: 8.9%   versus 6.6%  , and : not applicable. Data are shown as median [interquartile range]. Statistical analysis was performed using the 2-tailed Mann–Whitney test (, , , , and = not applicable, for 0, 12, 24, 36, and , resp.). Lines and whiskers represent median values and interquartile ranges, respectively. CD8 E: CD8 effectors. 0: no infusions, 12: from 1 to 12 infusions, 24: from 13 to 24 infusions, 36: from 25 to 36 infusions, and : over 36 infusions of natalizumab. ; ; ; .

(a)

(b)

(c)